|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
SundayWow! It's no wonder MS is seen as a Cash Cow: THESE MS DRUGS BROUGHT IN THE MOST MONEY LAST YEAR Teva
soaring out in front on a single product and it is no surprise that the
Generics pack are waiting in the rear ready for the copaxone patents to
expire starting May 2014. However Biogen are backing the most winners
with a staggering $5.8 billion worth of business. #2 Avonex Biogen Idec $3.0 billion #3 Gilenya Novartis $1.9 billion #4 Tysabri Biogen Idec $1.7 billion #5 Betaseron Bayer $1.1 billion #6 Tecfidera Biogen Idec $0.9 billion #7 Rebif EMD serono $0.6 billion #8 Ampyra Biogen Idec $0.3 billion #9 Aubagio Sanofi $0.2 billion #10 Extavia Novartis $0.2 billion Read more » Labels: 20 Best Stories & Studies, Ampyra, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Rebif, Tecfidera, Tysabri |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||